Inclusion Criteria:

          -  Histologically confirmed prostate cancer (mixed histology is acceptable, with the
             exception of the small cell pure phenotype, which is excluded)

          -  Received a taxane-based chemotherapy for the treatment of metastatic prostate cancer
             with evidence of disease progression on or after treatment, or discontinued from a
             taxane-based chemotherapy due to an adverse event

          -  Received a second-generation or later androgen receptor (AR)-targeted therapy (for
             example, abiraterone acetate plus prednisone, enzalutamide, apalutamide) for the
             treatment of metastatic prostate cancer with evidence of disease progression or
             non-metastatic castration-resistant prostate cancer with evidence of subsequent
             metastasis

          -  Biomarker-positive by at least one of the following criteria: (a) Biallelic
             deoxyribonucleic acid (DNA)-repair anomaly based on a sponsor validated blood or
             tissue assay; (b) Germline pathogenic Breast Cancer gene (BRCA) 1 or BRCA2 by any test
             (somatic local results must be confirmed as positive by the sponsor-validated assay
             before dosing)

          -  Progression of metastatic prostate cancer in the setting of castrate levels of
             testosterone or history of bilateral orchiectomy at study entry

        Exclusion Criteria:

          -  Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP)
             inhibitor

          -  Prior platinum-based chemotherapy for the treatment of prostate cancer

          -  Known history or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid
             leukemia (AML)

          -  Symptomatic or impending cord compression

          -  Symptomatic brain metastases